🇺🇸 FDA
Patent

US 12404237

Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

granted A61KA61K31/40A61K31/4025

Quick answer

US patent 12404237 (Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives) held by Takeda Pharmaceutical Company Limited expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/40, A61K31/4025, A61K31/422, A61K31/427